Quick Answer
Viking Therapeutics, Inc. reported Stockholders Equity of $639.06 million for fiscal year 2025.
Viking Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $639.06M | -27.4% |
| 2024 | $880.28M | +152.6% |
| 2023 | $348.42M | +139.8% |
| 2022 | $145.32M | -28.0% |
| 2021 | $201.88M | -17.4% |
| 2020 | $244.34M | -11.8% |
| 2019 | $277.12M | -6.9% |
| 2018 | $297.75M | +2111.5% |
| 2017 | $13.46M | +67.4% |
| 2016 | $8.04M | -7.8% |
| 2015 | $8.72M | +139.4% |
| 2014 | -$22.13M | -8730.1% |
| 2013 | -$250.6K | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $713.03M | -21.8% | -10.4% |
| June 30, 2025 | $795.46M | -13.6% | -6.1% |
| March 31, 2025 | $846.92M | -9.3% | -3.8% |
| December 31, 2024 | $880.28M | +152.6% | -3.4% |
| September 30, 2024 | $911.45M | +147.5% | -1.0% |
| June 30, 2024 | $920.98M | +138.5% | -1.4% |
| March 31, 2024 | $933.89M | +596.6% | +168.0% |
| December 31, 2023 | $348.42M | +139.8% | -5.4% |
- Viking Therapeutics, Inc. showed a decrease of -27.4% in Stockholders Equity compared to the prior fiscal year.
- Over the 2013–2025 period, Viking Therapeutics, Inc.’s stockholders equity has grown by 255108.7% (from -$250.6 thousand to $639.06 million).
- The most recent figure is from Viking Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 11, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: